South Korea Approves Vyepti for Migraine Prevention: A New Era in Neurological Care
June 1, 2026, 4:46 pm
Lundbeck announces Vyepti (eptinezumab) approval in South Korea for adult migraine prevention. This intravenous anti-CGRP monoclonal antibody offers a critical new treatment. Migraine affects 11% of the Korean population, a debilitating neurological condition often lacking adequate preventive options. Vyepti addresses this unmet need. The approval stems from robust Phase 3 trials, including SUNRISE, which involved a predominantly Asian chronic migraine population. Vyepti has demonstrated significant reductions in monthly migraine days, with rapid onset of action. This milestone expands global access to innovative brain health solutions, promising improved quality of life for countless patients struggling with severe, recurrent headaches, nausea, and light sensitivity. It represents a major advancement in neurological care.
South Korea grants marketing authorization for Vyepti. Eptinezumab, a preventive migraine treatment, gains approval. This marks a significant development for adults living with migraine in the region. The Ministry of Food and Drug Safety (MFDS) made the decision. Lundbeck, a biopharmaceutical company, announced the authorization.
Migraine is a severe neurological disorder. It causes debilitating headaches. Nausea, vomiting, and extreme sensitivity to light and sound often accompany attacks. This condition profoundly impacts daily life. It affects productivity and personal relationships. Migraine is not just a headache; it is a complex brain disease.
Globally, migraine impacts one in seven people. It stands as a leading cause of disability worldwide. In South Korea, approximately 11% of the population suffers from migraine. This figure may even be an underestimate. Despite its high prevalence, many patients lack adequate preventive treatment options. Significant gaps persist in diagnosis and access to effective care.
Vyepti offers a new solution. It targets the root causes of migraine. The drug is a humanized monoclonal antibody. It specifically binds to calcitonin gene-related peptide (CGRP). CGRP plays a key role in migraine pathways. By blocking CGRP, Vyepti prevents migraine attacks.
Vyepti is designed for intravenous (IV) administration. Patients receive the treatment through infusion. This delivery method ensures rapid and consistent drug levels. It offers a distinct advantage for some patients. Its mechanism of action provides immediate relief potential.
The South Korean approval rests on strong clinical evidence. Multiple Phase 3 trials support Vyepti's efficacy and safety. These trials include PROMISE-1, PROMISE-2, DELIVER, and SUNRISE. SUNRISE was particularly significant. It involved a predominantly Asian population. This trial focused on chronic migraine patients.
PROMISE-1 evaluated Vyepti in episodic migraine. PROMISE-2 assessed it for chronic migraine. Both trials met their primary endpoints. Vyepti consistently reduced monthly migraine days (MMDs). This benefit was observed for both 100 mg and 300 mg doses. The treatment effect began as early as Day 1 post-infusion. This rapid onset of action is crucial for patients seeking quick relief.
Clinical studies confirmed Vyepti's safety profile. More than 2,000 adult patients received at least one dose. Common adverse reactions included nasopharyngitis and hypersensitivity. Discontinuation rates due to adverse reactions were low. This demonstrates a favorable balance of benefit and risk.
Vyepti's journey began with U.S. FDA approval. The FDA authorized its use in February 2020. This positioned Vyepti as an early innovator in the CGRP class. European Union approval followed in January 2022. It covers adults experiencing at least four migraine days per month.
The drug has since expanded its global footprint. Vyepti is now available in more than 30 markets worldwide. South Korea joins this growing list. This broad availability underscores the global need for effective migraine prevention. It highlights Vyepti's role in addressing this need.
Lundbeck remains dedicated to brain health. The company focuses exclusively on neurological and psychiatric diseases. With over 70 years in neuroscience, Lundbeck innovates constantly. Their mission is to improve lives affected by brain disorders. Advancing brain health drives their research and development.
Brain disorders affect a vast population. Their societal impact is immense. Lundbeck strives to tackle complex neurological challenges. They develop transformative medicines. These target conditions with few existing treatments. Vyepti exemplifies this commitment.
The approval for Vyepti in South Korea aligns with Lundbeck's vision. It expands access to crucial therapies in Asia. Many patients in the region suffer a significant disease burden. This new option offers hope. It empowers patients to regain control over their lives.
Preventive treatments are vital. They break the cycle of repeated migraine attacks. They reduce reliance on acute medications. This helps prevent medication overuse headaches. Effective prevention can halt migraine chronification. Vyepti provides such a tool.
Patients will experience fewer migraine days. Their quality of life will improve. Family, social, and work lives can flourish. This approval is more than just market expansion. It represents a profound positive contribution to patient well-being.
Lundbeck continues to fight stigma surrounding brain disorders. They work to improve health equity. Delivering innovative therapies like Vyepti fulfills these commitments. It generates long-term value for patients, families, and society. This new authorization marks a major step forward for migraine care in Asia.
South Korea grants marketing authorization for Vyepti. Eptinezumab, a preventive migraine treatment, gains approval. This marks a significant development for adults living with migraine in the region. The Ministry of Food and Drug Safety (MFDS) made the decision. Lundbeck, a biopharmaceutical company, announced the authorization.
Migraine is a severe neurological disorder. It causes debilitating headaches. Nausea, vomiting, and extreme sensitivity to light and sound often accompany attacks. This condition profoundly impacts daily life. It affects productivity and personal relationships. Migraine is not just a headache; it is a complex brain disease.
Globally, migraine impacts one in seven people. It stands as a leading cause of disability worldwide. In South Korea, approximately 11% of the population suffers from migraine. This figure may even be an underestimate. Despite its high prevalence, many patients lack adequate preventive treatment options. Significant gaps persist in diagnosis and access to effective care.
Vyepti offers a new solution. It targets the root causes of migraine. The drug is a humanized monoclonal antibody. It specifically binds to calcitonin gene-related peptide (CGRP). CGRP plays a key role in migraine pathways. By blocking CGRP, Vyepti prevents migraine attacks.
Vyepti is designed for intravenous (IV) administration. Patients receive the treatment through infusion. This delivery method ensures rapid and consistent drug levels. It offers a distinct advantage for some patients. Its mechanism of action provides immediate relief potential.
The South Korean approval rests on strong clinical evidence. Multiple Phase 3 trials support Vyepti's efficacy and safety. These trials include PROMISE-1, PROMISE-2, DELIVER, and SUNRISE. SUNRISE was particularly significant. It involved a predominantly Asian population. This trial focused on chronic migraine patients.
PROMISE-1 evaluated Vyepti in episodic migraine. PROMISE-2 assessed it for chronic migraine. Both trials met their primary endpoints. Vyepti consistently reduced monthly migraine days (MMDs). This benefit was observed for both 100 mg and 300 mg doses. The treatment effect began as early as Day 1 post-infusion. This rapid onset of action is crucial for patients seeking quick relief.
Clinical studies confirmed Vyepti's safety profile. More than 2,000 adult patients received at least one dose. Common adverse reactions included nasopharyngitis and hypersensitivity. Discontinuation rates due to adverse reactions were low. This demonstrates a favorable balance of benefit and risk.
Vyepti's journey began with U.S. FDA approval. The FDA authorized its use in February 2020. This positioned Vyepti as an early innovator in the CGRP class. European Union approval followed in January 2022. It covers adults experiencing at least four migraine days per month.
The drug has since expanded its global footprint. Vyepti is now available in more than 30 markets worldwide. South Korea joins this growing list. This broad availability underscores the global need for effective migraine prevention. It highlights Vyepti's role in addressing this need.
Lundbeck remains dedicated to brain health. The company focuses exclusively on neurological and psychiatric diseases. With over 70 years in neuroscience, Lundbeck innovates constantly. Their mission is to improve lives affected by brain disorders. Advancing brain health drives their research and development.
Brain disorders affect a vast population. Their societal impact is immense. Lundbeck strives to tackle complex neurological challenges. They develop transformative medicines. These target conditions with few existing treatments. Vyepti exemplifies this commitment.
The approval for Vyepti in South Korea aligns with Lundbeck's vision. It expands access to crucial therapies in Asia. Many patients in the region suffer a significant disease burden. This new option offers hope. It empowers patients to regain control over their lives.
Preventive treatments are vital. They break the cycle of repeated migraine attacks. They reduce reliance on acute medications. This helps prevent medication overuse headaches. Effective prevention can halt migraine chronification. Vyepti provides such a tool.
Patients will experience fewer migraine days. Their quality of life will improve. Family, social, and work lives can flourish. This approval is more than just market expansion. It represents a profound positive contribution to patient well-being.
Lundbeck continues to fight stigma surrounding brain disorders. They work to improve health equity. Delivering innovative therapies like Vyepti fulfills these commitments. It generates long-term value for patients, families, and society. This new authorization marks a major step forward for migraine care in Asia.